Propanc Biopharma targets February 2027 first-patient dosing for Phase 1b PRP cancer trial
PPCB•Preclinical PRP data package released
Propanc Biopharma outlined new preclinical pancreatic cancer results for PRP, already presented in a newly released data package.
Studies showed strong tumor control, fewer metastases, longer survival, and signs of improved response to standard chemotherapy.
Differentiation-based approach and next catalyst
PRP uses a differentiation-based approach rather than RAS inhibition, positioning it as a potential complement to emerging RAS-targeted drugs.
The next catalyst is a planned Phase 1b first-in-human trial in advanced solid tumors, with first patient dosing targeted for February 2027.
